Instead in several neuromuscular disorders, such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and CHP1-associated ataxia, PLS3 overexpression acts as a protective modifier. This evidence concerns the gene CHP1 and amyotrophic lateral sclerosis.